|
Hybridoma
Generation and Characterization of a Novel Phospho-Specific Monoclonal Antibody to p120-catenin Serine 879
To cite this article:
Meredith H. Vaughan, Xiaobo Xia, Xiao Wang, Efthalia Chronopoulou, Guo-Jian Gao, Roberto Campos-Gonzalez, Albert B. Reynolds.
Hybridoma.
December 2007,
26(6): 407-416.
doi:10.1089/hyb.2007.0527.
Meredith H. Vaughan Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee. Xiaobo Xia Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee. Xiao Wang BD Bioscience/Cell Signaling Group, La Jolla, California. Efthalia Chronopoulou BD Bioscience/Cell Signaling Group, La Jolla, California. Guo-Jian Gao BD Bioscience/Cell Signaling Group, La Jolla, California. Roberto Campos-Gonzalez BD Bioscience/Cell Signaling Group, La Jolla, California. Albert B. Reynolds Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee. To better understand the mechanisms that regulate p120-catenin (p120) and E-cadherin function, we are systematically generating phospho-specific monoclonal antibodies (MAb) to the major p120 phosphorylation sites. p120 has emerged recently as a master regulator of E-cadherin stability and an important modulator of RhoGTPase activities. A number of phosphorylation sites have been identified, but none have as yet been linked to specific regulatory roles. Here, we describe a novel phospho-specific monoclonal antibody to the major PKC-induced p120 phosphorylation site, phospho-serine 879 (pS879). With a few exceptions, p120 MAb pS879 is remarkably specific for the phosphorylated S879 epitope and works effectively in common applications such as Western blot analysis, immunoprecipitation, and immunofluorescence. p120 MAb pS879 should facilitate efforts to identify the role of S879 phosphorylation and to map signaling pathways that modify p120 function through activation of PKC.
|
|